SAB Biotherapeutics, Inc. - SABS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G/A | Joseph Edelman | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 8.4% | 6,431,743 | View |
| May 15, 2026 | SCHEDULE 13G | Caligan Partners LP | 10.4% | 7,697,207 | View |
| May 15, 2026 | SCHEDULE 13G | JOHNSON DAVID EDWARD | 10.4% | 7,967,207 | View |
| May 15, 2026 | SCHEDULE 13G | Balyasny Asset Management L.P. | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | BAM GP LLC | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Balyasny Asset Management Holdings LP | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Dames GP LLC | 9.99% | 5,089,939 | View |
| May 15, 2026 | SCHEDULE 13G | Dmitry Balyasny | 9.99% | 5,089,939 | View |
| May 01, 2026 | SCHEDULE 13G | Millennium Management LLC | 5.1% | 3,432,153 | View |
| May 01, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 5.1% | 3,432,153 | View |
| May 01, 2026 | SCHEDULE 13G | Israel A. Englander | 5.1% | 3,432,153 | View |
| Mar 23, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
| Mar 11, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RTW Investments, LP | 3.2% | 1,587,302 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Roderick Wong | 3.2% | 1,587,302 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.1% | 2,540,159 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.1% | 2,540,159 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.9% | 1,931,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.9% | 1,931,905 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.5% | 225,556 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.5% | 225,556 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 8.6% | 4,472,064 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.1% | 4,761,906 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.1% | 4,761,906 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.1% | 4,761,906 | View |
| Jan 22, 2026 | SCHEDULE 13G | Perceptive Advisors LLC | 7.3% | 3,471,861 | View |
| Jan 22, 2026 | SCHEDULE 13G | Joseph Edelman | 7.3% | 3,471,861 | View |
| Jan 22, 2026 | SCHEDULE 13G | Perceptive Life Sciences Master Fund, Ltd. | 7.3% | 3,471,861 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.